X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (21) 21
humans (16) 16
male (14) 14
aged (13) 13
middle aged (13) 13
female (12) 12
diabetes (11) 11
treatment outcome (11) 11
mortality (10) 10
risk factors (10) 10
venous thromboembolism (10) 10
diabetes mellitus (9) 9
prevention (9) 9
type 2 diabetes (9) 9
cardiovascular diseases (8) 8
clinical trials (8) 8
dabigatran (8) 8
hematology (8) 8
peripheral vascular disease (8) 8
prophylaxis (8) 8
thromboembolism (8) 8
analysis (7) 7
dabigatran etexilate (7) 7
diabetes mellitus, type 2 - drug therapy (7) 7
double-blind (7) 7
double-blind method (7) 7
endocrinology & metabolism (7) 7
adult (6) 6
armour (6) 6
armoured or armed vehicles (6) 6
armoured turrets (6) 6
blasting (6) 6
glucose (6) 6
heating (6) 6
lighting (6) 6
means of attack or defence, e.g. camouflage, in general (6) 6
mechanical engineering (6) 6
weapons (6) 6
benzimidazoles - adverse effects (5) 5
cardiovascular disease (5) 5
cotransporter 2 inhibition (5) 5
direct thrombin inhibitor (5) 5
drug therapy (5) 5
enoxaparin (5) 5
hypoglycemic agents - therapeutic use (5) 5
orthopedics (5) 5
pulmonary embolism (5) 5
venous thromboembolism - etiology (5) 5
venous thromboembolism - prevention & control (5) 5
anticoagulants - adverse effects (4) 4
anticoagulants - therapeutic use (4) 4
benzhydryl compounds - therapeutic use (4) 4
benzimidazoles - administration & dosage (4) 4
benzimidazoles - therapeutic use (4) 4
cardiac & cardiovascular systems (4) 4
care and treatment (4) 4
dose-response relationship, drug (4) 4
empagliflozin (4) 4
enoxaparin - administration & dosage (4) 4
enoxaparin - adverse effects (4) 4
etexilate (4) 4
glucosides - therapeutic use (4) 4
hematology, oncology and palliative medicine (4) 4
hemorrhage - chemically induced (4) 4
internal medicine (4) 4
kidney diseases (4) 4
mellitus (4) 4
molecular-weight heparin (4) 4
risk assessment (4) 4
safety (4) 4
thrombin (4) 4
venous thromboembolism - drug therapy (4) 4
administration, oral (3) 3
anticoagulants - administration & dosage (3) 3
arthroplasty (3) 3
arthroplasty, replacement, knee - adverse effects (3) 3
bleeding (3) 3
blood glucose - metabolism (3) 3
cardiovascular diseases - prevention & control (3) 3
complications and side effects (3) 3
creatinine (3) 3
deep-vein thrombosis (3) 3
disease (3) 3
efficacy (3) 3
hospitalization (3) 3
hypoglycemic agents - adverse effects (3) 3
injections, subcutaneous (3) 3
kidneys (3) 3
knee replacement (3) 3
medical research (3) 3
medicine, experimental (3) 3
metaanalysis (3) 3
metformin (3) 3
myocardial infarction (3) 3
ortopedi (3) 3
patient outcomes (3) 3
placebo-controlled trial (3) 3
postoperative complications - prevention & control (3) 3
pyridines - administration & dosage (3) 3
pyridines - adverse effects (3) 3
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (61) 61
German (4) 4
French (2) 2
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Therapeutics, ISSN 0149-2918, 2016, Volume 38, Issue 6, pp. 1299 - 1313
Abstract Purpose The aim of this analysis was to establish the safety profile and tolerability of empagliflozin in patients with type 2 diabetes mellitus... 
Internal Medicine | Medical Education | adverse drug event | ketoacidosis | SGLT2 inhibitor | safety | hypoglycemia | METFORMIN | MONOTHERAPY | EFFICACY | PHARMACODYNAMICS | COTRANSPORTER 2 INHIBITION | ADD-ON THERAPY | PHARMACOKINETICS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | JAPANESE PATIENTS | Hypoglycemia - epidemiology | Benzhydryl Compounds - administration & dosage | Humans | Incidence | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Urinary Tract Infections - epidemiology | Clinical Trials, Phase III as Topic | Benzhydryl Compounds - adverse effects | Glucosides - administration & dosage | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - etiology | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Clinical Trials, Phase I as Topic | Glucosides - adverse effects | Clinical Trials, Phase II as Topic | Type 2 diabetes | Care and treatment | Safety and security measures | Analysis | Complications and side effects | Medical research | Medicine, Experimental | Urinary tract infections | Thromboembolism | Enzymes | Laboratories | Clinical trials | Infections | Glucose | Apolipoproteins | Patients | Low density lipoprotein | Insulin | Cholesterol | Studies | Fractures | Diabetes | Kidney diseases | Drug dosages
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 02/2018, Volume 41, Issue 2, pp. 356 - 363
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 22, pp. 2117 - 2128
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9591, pp. 949 - 956
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2016, Volume 37, Issue 19, pp. 1526 - 1534
Aims We previously reported that in the EMPA-REG OUTCOME(R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse... 
Cardiovascular disease | Mortality | Hospitalization | CARDIAC & CARDIOVASCULAR SYSTEMS | GUIDELINES | MELLITUS | COTRANSPORTER 2 INHIBITION | BLOOD-PRESSURE | DISEASES | COLLABORATION | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | WEIGHT | Fast Track | Aha Fasttrack | Editor's Choice
Journal Article
Age and Ageing, ISSN 0002-0729, 11/2019, Volume 48, Issue 6, pp. 859 - 866
Abstract Objective The risks of cardio-renal complications of diabetes increase with age. In the EMPA-REG OUTCOME® trial, empagliflozin reduced cardiovascular... 
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 06/2014, Volume 13, Issue 1, pp. 102 - 102
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 10/2019, Volume 116, Issue 44, pp. 22269 - 22274
Adrenocortical carcinomas (ACCs) are rare and highly malignant cancers associated with poor survival of patients. Currently, mitotane, a nonspecific derivative... 
Glutathione peroxidase | Cell culture | Transferrin | Carcinoma | Polyunsaturated fatty acids | Menopause | Pesticides | Fibrosarcoma | Antagonists | Iron | Insulin | Fatty acids |